← All trials
NCT03311932
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 16, 2018
- Primary completion
- Jul 13, 2018
- Completion date
- Jul 13, 2018
- First posted
- —
- Last posted
- —
- Enrollment
- 51
- Arms / groups
- 4 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Diurnal LimitedLead sponsor
- Emas Pharma Ltd.Collaborator
- Medical Matters InternationalCollaborator
- Brush Clinical Research Ltd.Collaborator
- Simbec-OrionOverall official - principal investigator
- Simbec-OrionCollaborator
- Voet ConsultingCollaborator
- Nichol Pharma Services Ltd.Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.